A user fee program for nonprescription (over-the-counter or OTC) monograph drugs would be a potential funding mechanism to supplement congressional non user-fee appropriations.
Similar Posts
Nefeteri Wellness – 709332 – 05/30/2025
Unapproved New DrugsCelestaPro – 718613 – 11/03/2025
Unapproved New Drugs/Misbranded BotoxNonprescription Drugs Advisory Committee Roster
This page contains the Nonprescription Drugs Advisory Committee Roster, which lists the current members and the current number of vacancies for the committee.Primavera Nueva Inc. Issues Voluntary Recall of Select 4-Count Tamales Because of Possible Health Risk- Revised to Include Roasted Pumpkin & White Cheddar, a Seasonal Item
Sonoma, CA — Primavera Nueva Inc. is voluntarily recalling certain lots of its 4-count tamales because the products have the potential to be contaminated with Listeria monocytogenes, an organism whichGeneric Drug Research Priorities & Projects
In accordance with the Generic Drug User Fee Amendments (GDUFA), FDA consults with industry and the public to create an annual list of regulatory science initiatives on generic drugs. These priorities are discussed and developed in public meetings and workshops, resulting in several awarded projectsOTC Monograph Reform: OTC Sunscreen Drugs – 12/15/2021
Webinar to discuss the deemed final order (DFO) for over-the-counter (OTC) sunscreen drugs and proposed order for OTC sunscreen drugs